LQDA Rule 144 Notice: 154,337 Common Shares via Fidelity, $4.31M
Rhea-AI Filing Summary
Liquidia Corporation (LQDA) filing a Form 144 reports a proposed sale of 154,337 common shares through Fidelity Brokerage Services with an aggregate market value of $4,312,469.02. The filing lists approximately 86,091,454 shares outstanding, and an approximate sale date of 08/28/2025. The shares to be sold were acquired on multiple dates: 392,156 shares on 04/13/2022 (secondary, cash), and earlier open-market purchases in 2018 and 2019 totaling additional shares. No securities were reported sold by the person in the past three months. The filer affirms they are not aware of undisclosed material adverse information and includes the standard Rule 144 representations.
Positive
- Clear compliance with Rule 144 requirements, including acquisition history and broker information
- No reported sales by the person in the past three months, reducing immediate aggregated-sale concerns
Negative
- None.
Insights
TL;DR: Routine Rule 144 notice for an insider or affiliated holder proposing a small block sale relative to outstanding shares.
The Form 144 discloses a proposed disposition of 154,337 common shares valued at $4.31 million through a broker on an indicated date. The filing includes specific acquisition dates and purchase types, which supports compliance with holding-period and manner-of-sale requirements under Rule 144. The proposed sale size represents a small fraction of the issuer's outstanding shares based on the numbers provided, suggesting limited market impact. There are no reported sales by this person in the prior three months, and the filer makes the customary representation regarding material nonpublic information.
TL;DR: Disclosure follows standard Rule 144 practice; documentation of acquisition history and broker use reduces procedural risk.
The filing provides clear acquisition records (dates, amounts, and payment method) and identifies the executing broker, which supports transparency and regulatory compliance. The attestation that no undisclosed material adverse information is known is standard and important for Section 10b5-1 trading-plan considerations if applicable. There is no indication in the document of any governance or insider-control issues arising from this notice alone.